• Rocket Pharmaceuticals signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 180 million.
• Voucher was awarded following FDA accelerated approval of KRESLADI (marnetegragene autotemcel).
• Proceeds will fund Rocket’s cardiovascular gene therapy pipeline.
• Cash runway is expected to extend into Q2 2028 on a pro forma basis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604280700BIZWIRE_USPR_____20260428_BW133676) on April 28, 2026, and is solely responsible for the information contained therein.